Stoff-Khalili M A, Dall P, Curiel D T
Division of Human Gene Therapy, Departments of Medicine, Surgery, Pathology and the Gene Therapy Center, University of Alabama at Birmingham, Birminham, AL, USA.
Cancer Gene Ther. 2006 Jul;13(7):633-47. doi: 10.1038/sj.cgt.7700929. Epub 2006 Jan 6.
In view of the limited success of available treatment modalities for breast cancer, alternative and complementary strategies need to be developed. The delineation of the molecular basis of breast cancer provides the possibility of specific intervention by gene therapy through the introduction of genetic material for therapeutic purposes. In this regard, several gene therapy approaches for carcinoma of the breast have been developed. These approaches can be divided into six broad categories: (1) mutation compensation, (2) molecular chemotherapy, (3) proapoptotic gene therapy, (4) antiangiogenic gene therapy, (5) genetic immunopotentiation, and (6) genetic modulation of resistance/sensitivity. Clinical trials for breast cancer have been initiated to evaluate safety, toxicity, and efficacy. Combined modality therapy with gene therapy and chemotherapy or radiation therapy has shown promising results. It is expected that as new therapeutic targets and approaches are identified and advances in vector design are realized, gene therapy will play an increasing role in clinical breast cancer treatment.
鉴于现有乳腺癌治疗方式的成效有限,需要开发替代和补充策略。乳腺癌分子基础的阐明为通过引入用于治疗目的的遗传物质进行基因治疗的特异性干预提供了可能性。在这方面,已经开发了几种针对乳腺癌的基因治疗方法。这些方法可大致分为六大类:(1) 突变补偿,(2) 分子化疗,(3) 促凋亡基因治疗,(4) 抗血管生成基因治疗,(5) 基因免疫增强,以及 (6) 耐药性/敏感性的基因调控。已经启动了乳腺癌的临床试验以评估安全性、毒性和疗效。基因治疗与化疗或放疗的联合治疗已显示出有前景的结果。预计随着新的治疗靶点和方法被确定以及载体设计取得进展,基因治疗将在临床乳腺癌治疗中发挥越来越重要的作用。